QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
NYSEAMERICAN:NBY

NovaBay Pharmaceuticals (NBY) Stock Forecast, Price & News

$0.48
+0.01 (+2.11%)
(As of 09/26/2023 ET)
Compare
Today's Range
$0.46
▼
$0.50
50-Day Range
$0.60
▼
$1.15
52-Week Range
$0.42
▼
$4.38
Volume
255,638 shs
Average Volume
604,125 shs
Market Capitalization
$2.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

NBY stock logo

About NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Stock

NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through traditional and digital beauty retailers and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

NBY Price History

NBY Stock News Headlines

September 11, 2023 | marketwatch.com
NovaBay Pharma Shares Rise 42% After Deal With BioStem Technologies
September 11, 2023 | markets.businessinsider.com
NovaBay Pharma Agrees With BioStem To Commercialize Amniotic Tissue Allograft As Avenova Allograft
September 26, 2023 | Micro-Cap Stock Trader (Ad)
Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
September 11, 2023 | benzinga.com
Why NovaBay Pharmaceuticals Stock Is Blasting Higher
September 11, 2023 | msn.com
NovaBay stock soars 86% on optic allograft product deal
September 11, 2023 | marketwatch.com
NovaBay to Commercialize BioStem Technologies' Amniotic Tissue Allograft
September 11, 2023 | finance.yahoo.com
NovaBay Pharmaceuticals Announces Agreement with BioStem Technologies to Commercialize Amniotic Tissue Allograft as Avenova® Allograft
August 15, 2023 | finance.yahoo.com
NovaBay Pharmaceuticals, Inc. (AMEX:NBY) Q2 2023 Earnings Call Transcript
September 26, 2023 | Micro-Cap Stock Trader (Ad)
Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
August 12, 2023 | msn.com
Ladenburg Thalmann Maintains Novabay Pharmaceuticals (NBY) Buy Recommendation
August 11, 2023 | finance.yahoo.com
Q2 2023 NovaBay Pharmaceuticals Inc Earnings Call
August 11, 2023 | finance.yahoo.com
NovaBay Pharmaceuticals Reports Second Quarter 2023 Financial Results
August 10, 2023 | markets.businessinsider.com
NovaBay Pharmaceuticals earnings preview: what Wall Street is expecting
August 8, 2023 | finance.yahoo.com
NovaBay Pharmaceuticals to Hold Second Quarter 2023 Conference Call on August 10, 2023
July 14, 2023 | finance.yahoo.com
NovaBay Pharmaceuticals Reports Record Avenova Sales Day
July 10, 2023 | markets.businessinsider.com
NovaBay Pharma: Avenova-Branded Products To Be Available Exclusively During Amazon Prime Day
July 10, 2023 | finance.yahoo.com
NovaBay Pharmaceuticals Announces Exclusive Amazon Prime Day 2023 Promotions on All Avenova-Branded Products
June 28, 2023 | benzinga.com
Analyst Covering NovaBay Pharmaceuticals Models For 1346% Upside, Issues $12 PT ($NBY)
June 28, 2023 | finance.yahoo.com
NovaBay Pharmaceuticals Supports National Dry Eye Awareness Month with Educational Programs and Avenova Product Promotions
June 20, 2023 | benzinga.com
NovaBay Pharmaceuticals Advancing Products Portfolio Earns Analyst Price Target 1638% Higher Than Current ($NBY)
June 20, 2023 | finance.yahoo.com
NovaBay Pharmaceuticals to Showcase its Full Line of Avenova Eyecare Products at the 126th Annual American Optometric Association Congress
June 12, 2023 | finance.yahoo.com
NovaBay Pharmaceuticals Announces DERMAdoctor’s KP Duty Lotion and Scrub Ultra Duo Set for Dry, Rough, Bumpy Skin to be Featured on QVC at a Special Price
June 2, 2023 | fool.com
NovaBay Pharmaceuticals (NYSEMKT: NBY)
May 30, 2023 | finance.yahoo.com
Presenting on the Emerging Growth Conference on May 31 Register Now
May 24, 2023 | proactiveinvestors.com
NovaBay Pharmaceuticals looking to grow its three verticals, eye, skin, and wound care in 2023
May 24, 2023 | finance.yahoo.com
NovaBay Pharmaceuticals to Present at the Emerging Growth Virtual Conference on May 31, 2023
May 11, 2023 | msn.com
NovaBay Pharmaceuticals: Q1 Earnings Insights
See More Headlines
Receive NBY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NovaBay Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

NBY Company Calendar

Last Earnings
8/10/2023
Today
9/26/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSEAMERICAN
Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSEAMERICAN:NBY
CUSIP
N/A
CIK
1389545
Web
novabay.com
Phone
(510) 899-8800
Fax
510-474-1577
Employees
29
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($9.9465)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-10,610,000.00
Net Margins
-79.70%
Pretax Margin
-79.70%
Return on Equity
-146.20%
Return on Assets
-69.63%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.85
Quick Ratio
1.25

Sales & Book Value

Annual Sales
$14.40 million
Price / Sales
0.14
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.53 per share
Price / Book
0.32

Miscellaneous

Outstanding Shares
4,210,000
Free Float
4,160,000
Market Cap
$2.06 million
Optionable
Not Optionable
Beta
2.82
Investing Strategies To Help Grow Your Retirement Income Cover
Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Justin M. Hall Esq. (Age 45)
    Pres, CEO, Gen. Counsel, Chief Compliance Officer, Corp. Sec. & Director
    Comp: $364.95k
  • Dr. Audrey Kunin M.D. (Age 64)
    Chief Product Officer
    Comp: $204.4k
  • Mr. Tommy Law (Age 37)
    Controller, Interim CFO & Treasurer
  • Dr. Jeffrey Kunin M.D. (Age 60)
    Pres of DERMAdoctor

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













NBY Stock - Frequently Asked Questions

How have NBY shares performed in 2023?

NovaBay Pharmaceuticals' stock was trading at $1.95 at the start of the year. Since then, NBY stock has decreased by 74.9% and is now trading at $0.49.
View the best growth stocks for 2023 here.

How were NovaBay Pharmaceuticals' earnings last quarter?

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) issued its quarterly earnings data on Thursday, August, 10th. The biopharmaceutical company reported ($1.27) earnings per share for the quarter. The biopharmaceutical company had revenue of $4.61 million for the quarter. NovaBay Pharmaceuticals had a negative net margin of 79.70% and a negative trailing twelve-month return on equity of 146.20%.

When did NovaBay Pharmaceuticals' stock split?

NovaBay Pharmaceuticals's stock reverse split on Wednesday, November 16th 2022. The 1-35 reverse split was announced on Wednesday, November 16th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 16th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of NovaBay Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NovaBay Pharmaceuticals investors own include Aeterna Zentaris (AEZS), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Bionano Genomics (BNGO), Heat Biologics (HTBX), iBio (IBIO), Matinas BioPharma (MTNB), Novan (NOVN), ADMA Biologics (ADMA) and Vaxart (VXRT).

What is NovaBay Pharmaceuticals' stock symbol?

NovaBay Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NBY."

Who are NovaBay Pharmaceuticals' major shareholders?

NovaBay Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (1.65%). Insiders that own company stock include Andrew D Jones, Audrey Kunin, Jeffrey Kunin and Justin Hall.
View institutional ownership trends.

How do I buy shares of NovaBay Pharmaceuticals?

Shares of NBY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NovaBay Pharmaceuticals' stock price today?

One share of NBY stock can currently be purchased for approximately $0.49.

How much money does NovaBay Pharmaceuticals make?

NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) has a market capitalization of $2.06 million and generates $14.40 million in revenue each year. The biopharmaceutical company earns $-10,610,000.00 in net income (profit) each year or ($9.9465) on an earnings per share basis.

How can I contact NovaBay Pharmaceuticals?

NovaBay Pharmaceuticals' mailing address is 2000 Powell St Ste 1150, EMERYVILLE, CA 94608-1804, United States. The official website for the company is novabay.com. The biopharmaceutical company can be reached via phone at (510) 899-8800, via email at jcain@lhai.com, or via fax at 510-474-1577.

This page (NYSEAMERICAN:NBY) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -